Definium Therapeutics Announces Fiscal Quarter Results Ended June 30, 2026

What Happened

• On August 6, 2026, Definium Therapeutics, Inc. announced its financial results for the fiscal quarter ended June 30, 2026 and disclosed a conference call to discuss those results and recent corporate highlights. The company furnished the press release as Exhibit 99.1 to its Form 8-K filed the same day. The report was signed by CEO Robert Barrow.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02 / Item 9.01).
• Reporting period: fiscal quarter ended June 30, 2026.
• Press release announcing quarterly results and conference call furnished as Exhibit 99.1.
• 8-K signed on behalf of the company by Chief Executive Officer Robert Barrow.

Why It Matters

• This filing signals that Definium has released its quarterly earnings and operational update—material information for shareholders and prospective investors. Retail investors should review the furnished press release and listen to the conference call for specifics on earnings, revenue, cash position, and any updates on the company’s clinical or commercial progress, since those details drive valuation and near-term outlook.